Arca
Skip to content
Tools
Tools

D-lactose

Small molecule in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 0
  • In phases 1 to 3: 2
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 2

Approved0

    Phase 32

    • Lactase
    • Tilactase

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        LactasePhase 3Eurofarma Laboratorios S.A.Protein or peptideHydrolytic enzymeD-lactose hydrolytic enzyme6
        TilactasePhase 3Bio Sidus SAProtein or peptideHydrolytic enzymeD-lactose hydrolytic enzyme4

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 6 in all, from ClinicalTrials.gov.
        Prenatal Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis Clinical TrialLactasePhase 1Not yet recruitingTippi MackenzieMar 18, 2026
        Effect OF Lactase Enzyme Supplements ON Intolerance IN Preterm NeonatesLactase, TilactaseNot applicableRecruitingAlexandria UniversityJul 28, 2025
        Proper Dietary Management, Follow-up, and Lactase Enzyme Supplementation for Lactose IntoleranceLactase, Tilactase—RecruitingEuropean Institute of OncologyJan 14, 2025
        Milk for Diabetes PreventionLactase, TilactaseNot applicableRecruitingAlbert Einstein College of MedicineJul 22, 2024
        The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)Lactase, TilactaseNot applicableNot yet recruitingUniversity of PecsOct 29, 2021
        A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 GangliosidosisLactasePhase 1 / Phase 2RecruitingNational Human Genome Research Institute (NHGRI)May 16, 2019

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4632342, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.